<DOC>
	<DOCNO>NCT00275379</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled , parallel-design , exploratory study orally administer ERB-041 subject active IC . The primary objective study investigate ERB-041 ’ activity level urinary APF , explore gene expression response peripheral blood mononuclear cell ( PBMC ) , evaluate safety ERB-041 woman active IC .</brief_summary>
	<brief_title>Study Evaluating Orally Administered ERB-041 Subjects With Active Interstitial Cystitis</brief_title>
	<detailed_description />
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Subjects seek medical treatment symptom consistent IC ongoing &gt; 9 month seek medical treatment previous document diagnosis IC Subjects surgically sterile postmenopausal ( amenorrheic &gt; 12 month ) must agree commit use medically acceptable , highly–effective ( i.e . doublebarrier IUD ) , nonhormonal form birth control study 30 day last dose test Use herbal supplement ( except daily multivitamin/mineral supplement contain herbal component ) History cancer ( resect cutaneous basal squamous cell carcinoma situ cervical cancer ) less 5 year documentation diseasefree state Vaginitis vaginal infection within 1 month randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Cystitis</keyword>
</DOC>